@Memo0606 am now in for the long term. I don't think the valuation is too high. MEDP is virtually a shovel manufacturer in an important sector of the future
@Memo0606 fantastic margins (80 Gross, >30 Net, >20 FCF), favorable in historical comparison. The product positioning in the high-margin segments (animals, cancer) and especially the latter is likely to be a growth market. At the moment, everyone is only looking at Eli Lilly, which is why this could be an anti-cyclical play in the sector. I like how the management handles cash (conservative). Only the relatively high level of debt is a negative point. Sales growth is currently low. But profit and FCF growth is extremely high (due to base effects). The valuation of 13 P/E is quite favorable in my opinion. Oh and Merck is also a long-term runner, compounder or quality stock with a discount
@Memo0606 I will probably go in in installments, but I don't know when yet.
You can consider a momentum discount strategy against the "runaway". For example, you buy when it rises/falls above 108 or below 101. Then you either have a low price and if it doesn't fall that low, you're still in. Or you go in in very small tranches. Then you at least have a few shares should it run away from you
